The impact of combination therapy with Femoklim and Nervo-Vit on the indicators of anxiety and social activity in premenopausal patients with estrogen deficiency

DOI: https://doi.org/10.29296/25877305-2022-10-11
Issue: 
10
Year: 
2022

M. Khabibulina, Candidate of Medical Sciences; M. Shamilov
Ural State Medical University, Yekaterinburg

The efficiency of combination therapy with the natural non-hormonal agent Femoklim and the combined sedative drug Nervo-Vit and its effect on the parameters of social functioning and the levels of anxiety were evaluated in 45 premenopausal patients with hypoestrogenemia. The Hospital Anxiety and Depression Scale (HADS) was used to assess psychological characteristics. The degree of stressful effect of estrogen deficiency on the social aspects of life in the examined female patients was measured according to the Sheehan visuospatial subscales. Therapy with these drugs was found to reduce the level of anxiety and had a positive effect on the social aspects of life in premenopausal women with estrogen deficiency. The degree of stressful influence of estrogen deficiency on the social aspects of life in the examined patients was measured according to the visual-spatial subscales D.V. Sheehan. Therapy with these drugs was established to reduce the level of anxiety and had a positive effect on the social aspects of life in premenopausal women with estrogen deficiency.
Keywords: 
therapy
anxiety
social functioning
premenopause
hypoestrogenemia
Femoklim
Nervo-Vit

References: 
  1. Chazova I.E., Smetnik V.P., Balan V.E. Vedenie zhenshchin s serdechno-sosudistym riskom v peri- i postmenopauze:konsensus rossiiskikh kardiologov i ginekologov. Consilium medicum. 2008; 10 (6): 5–18 (in Russ.).
  2. Skornyakova M.N., Syrochkina M.A. Gipomenstrual'nyi sindrom. Rukovodstvo dlya vrachei. Ekaterinburg, 2008; 236 s. (in Russ.).
  3. Smetnik V.P., Il'ina L.M. Korrektsiya klimaktericheskogo sindroma (individualizatsiya terapii). V kn. «Meditsina klimakteriya». Litera, 2006; s. 217–74 (in Russ.).
  4. Khabibulina M.M. Kardiovaskulyarnyi risk pri estrogenodefitsite v doklimaktericheskikh periodakh.Yekaterinburg, 2014 (in Russ.).
  5. Blumel J.E., Castello C. et al. Quality of life after the menopause – a population study. Maturitas. 2009; 34 (1): 17–23. DOI: 10.1016/s0378-5122(99)00081-x
  6. Khabibulina M.M. Effect of hypoestrogenemia on quality of life of premenopausal women with arterial hypertension. Kardiologiya. 2013; 53 (11): 45–8 (in Russ.).
  7. Khabibulina M.M., Dmitriev A.N., Fedorova N.N. Kachestvo zhizni molodykh zhenshchin s arterial’noi gipertenziei s gipoestrogenemiei s «metabolicheski zdorovym» vistseral’nym ozhireniem. Evraziiskii Soyuz Uchenykh. 2017; 1 (34): 25–9 (in Russ.).
  8. Khabibulina M., Shamilov M. Quality of life in young women with hypertension and an altered hormonal background. Vrach. 2021; 32 (1): 46–9 (in Russ.). DOI: 10.29296/25877305-2021-01-09
  9. Stein K.D., Jacobsen P.B. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom. 2009; 19: 436–45.
  10. Khabibulina M.M., Smolentseva A.A. Terapiya trevozhnykh rasstroistv u zhenshchin s arterial'noi gipertenziei v period premenopauzy na ambulatornom etape. V sb.: V s"ezd kardiologov Ural'skogo federal'nogo okruga. Mat-ly s"ezda. 2011; s. 282–4 (in Russ.).
  11. Dedov D., Mukailov N., Evtyukhin I. Quality of life and prognosis in AH and CHD patients with atrial fibrillation. Vrach. 2013; 7: 72–4 (in Russ.).
  12. Menopauzal'naya gormonal'naya terapiya i sokhranenie zdorov'ya zhenshchin zrelogo vozrasta: Klinicheskie rekomendatsii (protokol lecheniya). M.: FGBU NTsGAiP, 2015 (in Russ).
  13. Pines A., Sturdee D.W., Birkhauser M.H. IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric. 2007; 10 (3): 195–6. DOI: 10.1080/13697130701361657
  14. Khabibulina M.M., Dmitriev A.N. Sposob optimizatsii lecheniya zhenshchin kardiotropnoi terapiei i zamestitel'noi gormonal'noi terapiei pri estrogenodefitsite s arterial'noi gipertenziei v pozdnem reproduktivnom periode. Patent na izobretenie RU 2648470 C2, 26.03.2018 Zayavka №2016107890 ot 03.03.2016 (in Russ.).
  15. Khabibulina M. Therapy in women with hypertension and estrogen deficiency in the late fertile period. Vrach. 2016; 4: 45–9 (in Russ.).
  16. Zigmond A.S., Snaith R.P. Тhe hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67: 361. DOI: 10.1111/j.1600-0447.1983.tb09716.x
  17. Sheehan D.V., Harnett-Sheehan K., Raj B.A. The measurement of disability. Int Clin Psychopharmacol. 1996; 11 (3, Suppl.): 89–95. DOI: 10.1097/00004850-199606003-00015
  18. Trussell J., Jordan B. Reproductive health risks in perspective. Contraception. 2006; 73: 437–9. DOI: 10.1016/j.contraception.2006.01.008
  19. Ovsyannikova T.V., Makarov I.O., Kulikov I.A. Clinical efficacy of non-hormonal methods of therapy in perimenopausal women. Obstetrics, Gynecology and Reproduction. 2013; 7 (3): 26–9 (in Russ.).
  20. Petrova E., Kalistratov V., Polyboyarinov P. et al. The menopause drug Femo-Klim is the best nonhormonal solution of hormonal problems. Vrach. 2019; 30 (1): 46–9 (in Russ.). DOI: 10.29296/25877305-2019-01-08
  21. Radzinskii V.E., Dobretsova T.A. Menopauza kak mekhanizm zhenskogo stareniya. Fitoestrogeny – razvedka boem. StatusPraesens. Ginekologiya. Akusherstvo. Besplodnyi brak. 2015; 2 (25): 51–8 (in Russ.).
  22. Radzinskii V.E., Dobretsova T.A., Ryzhova T.E. Biologicheskaya rol' menopauzal'nogo perekhoda i terapevticheskie vozmozhnosti fitoestrogenov. StatusPraesens. Ginekologiya. Akusherstvo. Besplodnyi brak. 2015; 4 (27): 77–82 (in Russ).
  23. Tatarova N.A., Linde V.A., Zhidkova E.V. et al. Negormonal'naya korrektsiya klimaktericheskikh rasstroistv v peri- i postmenopauze. Effektivnaya farmakoterapiya v akusherstve i ginekologii. 2009; 17: 12–5 (in Russ.).